Rx Review 2024: Discovering the Latest & Greatest in Pharmacotherapy - Live Webinar on July 9, 2024 8PM ET
The course offers a deep dive into the 37 new pharmaceutical agents, highlighting the fact that 54% of these were first-in-class. Healthcare professionals will be educated on how these new agents align with current management guidelines, their mechanism of action, dosing, side effects, clinical efficacy, and costs.
About this webinar
This comprehensive course is designed to navigate the complex world of novel pharmaceuticals that gained FDA approval in the previous year. The course offers a deep dive into the 37 new pharmaceutical agents, highlighting the fact that 54% of these were first-in-class. Healthcare professionals will be educated on how these new agents align with current management guidelines, their mechanism of action, dosing, side effects, clinical efficacy, and costs. Special emphasis will be placed on agents related to Ambulatory Care practice models as they represent the majority of 2022’s approved drugs.
The course content is methodically arranged according to organ systems, making it easier for learners to integrate this knowledge into existing management guidelines for conditions such as cardiovascular disease and diabetes. Detailed information on each agent’s class designation, mechanism of action, dosing, clinical efficacy, side effects, and cost will be provided. The course concludes with a set of practical recommendations and a discussion on maintaining up-to-date practice standards in the ever-evolving healthcare landscape.
At the conclusion of this continuing education activity, the participant will be able to:
Identify the new pharmaceutical agents available for clinical practice.
Outline the use of new pharmaceutical agents in clinical practice.
Explain the benefits, risks, and alternatives of new pharmaceutical agents.
